Advertisement

Topics

Magenta Therapeutics presents updated Phase 2 clinical data on MGTA-456 cell therapy

06:42 EDT 10 May 2019 | Pharmaceutical Business Review

MGTA-456 is a cell therapy designed to provide a high dose of hematopoietic stem cells that are well-matched to the patient. The Company plans to enroll 12 patients

The post Magenta Therapeutics presents updated Phase 2 clinical data on MGTA-456 cell therapy appeared first on Pharmaceutical Business review.

Original Article: Magenta Therapeutics presents updated Phase 2 clinical data on MGTA-456 cell therapy

NEXT ARTICLE

More From BioPortfolio on "Magenta Therapeutics presents updated Phase 2 clinical data on MGTA-456 cell therapy"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Stem Cells
Track and monitor developments in stem cell research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on stem cells and follow companies active in the stem cell industry.  BioPort...